“Comparative Efficacy of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Treatment Response in Atopic Dermatitis at Varying Treatment Continuance Rates”, J of Skin, vol. 9, no. 1, p. s519, Jan. 2025, doi: 10.25251/skin.9.supp.519.